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Abstract: Ruxolitinib is an orally bioavailable, selective Janus kinase (JAK) 1 and 2 inhibitor 
approved for the treatment of myelofibrosis (MF), a bone marrow disease in which the JAK 
pathway is dysregulated, leading to impaired hematopoiesis and immune function. By inhibiting 
JAK1 and JAK2, ruxolitinib modulates cytokine-stimulated intracellular signaling. In a 
phase II clinical trial in patients with MF, ruxolitinib recipients exhibited durable reductions 
in spleen size, reductions in circulating pro-inflammatory cytokines, improvements in   physical 
activity, weight gain, and alleviation of symptoms (including constitutional symptoms) in 
patients with and without JAK2 mutation. These findings were confirmed by two phase III 
clinical MF   studies, in which a greater proportion of ruxolitinib recipients achieved a spleen 
volume   reduction of $35% from baseline at week 24, compared with placebo in one study 
(41.9% versus 0.7%; P , 0.0001) and with best available therapy in the other (31.9% versus 0%; 
P , 0.0001). Alleviation of MF symptoms and improvements in quality of life were also 
significantly greater in ruxolitinib recipients. Overall survival of patients treated with ruxolitinib 
was significantly longer than of those receiving the placebo. Owing to risks of potentially 
serious adverse effects, eg, myelosuppression, ruxolitinib should be used under close physician 
supervision. Longer follow-up of the phase III MF studies is needed to reach firm conclusions 
regarding ruxolitinib’s capacity to modify the natural disease course.
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Introduction
Myelofibrosis (MF) is a bone marrow disease characterized by excessive production 
of reticulin and collagen fibers. Although fibrosis can be the outcome of numerous 
hematologic and nonhematologic conditions,1 the term MF is commonly used in 
reference either to primary MF (PMF)2 or to the similar disorders evolving from the 
two other classic Philadelphia-chromosome-negative myeloproliferative neoplasms: 
polycythemia vera (post-PV MF) and essential thrombocythemia (post-ET MF).3 
According to epidemiological studies,4–9 the incidence of PMF may be as high as 1.5 
per 100,000. Other studies10–14 show that by the end of the second decade after PV or 
ET diagnosis, up to 10%–15% of cases may transform to secondary MF.
In MF, the fibrotic changes appear to be cytokine-stimulated reactions sustained 
by multilineage clonal cellular proliferation.15–21 The clinical signs of MF include 
splenomegaly due to extramedullary hematopoiesis; leukocytosis and thrombocytosis, 
with predisposition to thrombotic events, due to clonal cellular proliferation affecting 
mainly megakaryocytes and granulocytes; cytopenias, a later finding that worsens 
with the progression of fibrosis; and constitutional symptoms (eg, fatigue, weight 
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loss,   low-grade fever, night sweats), most likely induced by 
abnormal levels of circulating cytokines.
In the past decade, the role of Janus kinases (JAKs) in 
intracellular pathways has claimed the attention of many 
myeloproliferative neoplasm researchers. JAKs are non-
receptor tyrosine kinases that mediate the transmission of 
cytokine- and growth-factor-induced intracellular signals 
(Figure 1). About 50% of patients with PMF present with 
the JAK2V617F gain-of-function mutation, resulting in a con-
stitutively activated JAK-signal transducer and activator of 
transcription (JAK-STAT) pathway.22,23 In turn, the activated 
JAK-STAT pathway promotes the transcription of numerous 
genes, eg, for cytokines, fibrogenic factors, and angiogenic 
factors, among a broad variety of pro-proliferative and 
anti-apoptotic gene products.24–29 Excessive production of 
pro-inflammatory cytokines may itself contribute to JAK-
STAT activation,30 creating a vicious cycle. Among patients 
with MF, about 5% are JAK2V617F-negative but instead have 
a gain-of-function mutation in the thrombopoietin receptor 
gene (MPL W515 L mutation), resulting in cytokine-independent 
JAK-STAT activation.31,32 Another small group of patients 
with MF have neither of these mutations but carry other 
Figure 1 The JAK-STAT intracellular signaling pathway in myelofibrosis. Copyright © 2011, Nature Publishing Group. Reproduced with permission from Quintàs-Cardama 
A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10(2):127–140.60
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mutations (eg, in lymphocyte adaptor protein33 or in the recep-
tor adaptor protein CBL)34 associated with constitutive JAK2 
activation. Moreover, patients with MF in the absence of any 
identified mutation often exhibit JAK2 overactivity. JAK1 
also plays a role in MF: a recent study30 demonstrated JAK1 
hyperactivity in MF patients, most likely as a consequence of 
cytokine hyperstimulation. Collectively, these data implicate 
JAK1 and JAK2 as important pieces in the puzzle posed by 
the molecular pathogenesis of MF.
Currently, the only potentially curative treatment for 
MF is allogeneic hematopoietic stem cell transplantation, 
an option traditionally feasible only for a small subgroup of 
patients, the younger and physically fit, although new reports 
suggest its utility in the older patients as well.35,36 Other treat-
ment modalities (eg, hydroxyurea, anagrelide, splenectomy 
or splenic irradiation, lenalidomide or thalidomide with or 
without corticosteroids, transfusions, danazol, androgens) 
are only palliative and without a substantial influence on 
survival.37–53 Patients often die from bone marrow failure 
accompanied by systemic infection or fatal hemorrhage.20,54,55 
However, with the discovery of the JAK2V617F mutation,56–59 
JAK2 emerged as a potential target for treatment, and several 
small-molecule, ATP-competitive JAK2 inhibitors were 
developed (SAR302503 [TG101348], lestaurtinib [CEP-701], 
XL019, SB1518, CYT387, AZD1480, and ruxolitinib).60–63 
Ruxolitinib (formerly known as INCB018424) is the first and 
currently the only JAK inhibitor approved by the US Food 
and Drug Administration or any other regulatory agency for 
treatment of patients with MF;64 and clinical development of 
several JAK inhibitors (SAR302503 [TG101348], CYT387, 
and LY278544) is ongoing. Although not as developed 
as ruxolitinib, available data on the efficacy of the other 
JAK2 inhibitors suggests similar profiles, mainly reduction in 
the size of enlarged organs (splenomegaly and hepatomegaly) 
and elimination of MF-related symptoms. The differences 
among them so far are mainly seen in relation to their toxicity 
profiles, eg, a degree of myelosuppression, gastrointestinal 
and/or neurological side effects.
Preclinical studies of ruxolitinib
Ruxolitinib phosphate (Figure 2) is an orally administered 
ATP-competitive cyclopentylpropionitrile derivative. 
In   preclinical studies, it showed inhibitory activity 
in vitro mainly against JAK1 (IC50 = 3.3 nM) and JAK2 
(IC50 = 2.8 nM).30 Moderate to minimal inhibitory activity 
was observed against nonreceptor tyrosine kinase TYK2 
(half-maximal inhibitory concentration [IC50] = 19 nM) and 
against JAK3 (IC50 = 428 nM), as well as minimal inhibitory 
activity against multiple other kinases at concentrations about 
100-fold higher than the IC50 for JAK1/2.30 Selectivity against 
JAK1/2 was confirmed by measurements of STAT activity 
in a cytokine-stimulated whole-blood assay.30
In an engineered cell system containing growth-
factor-independent JAK2V617F-expressing Ba/F3 cells 
(Ba/F3-EpoR-JAK2V617F), ruxolitinib demonstrated a 
dose-dependent reduction of JAK2-mediated downstream 
phosphorylated proteins with no change in their total 
levels,30 suggesting that ruxolitinib exerts its effect through 
achievement of reduced levels of phosphorylated (active) 
forms. A similar effect was observed in the HEL cell line.30 
In these cell lines and in cells from mononuclear PV patients, 
ruxolitinib demonstrated antiproliferative and proapoptotic 
effects.30 Analogous effects were not observed on BCR-
ABL-1 signaling or in a cell line expressing an activating 
mutation in c-KIT.30 The effects of ruxolitinib were attenu-
ated when cells expressing JAK2V617F were cocultured with 
primary or immortalized human bone marrow mesenchymal 
Table 1 Examples of strong cytochrome P450 3A4 inhibitors with 
potential influence on the pharmacokinetics of coadministered 
ruxolitinib71,72
Drug
Ketoconazolea
Itraconazolea
Posaconazole
Voriconazole
Clarithromycin
Telithromycin
Atazanavir
Indinavir
Nelfinavir
Ritonavir
Saquinavir
Nefazodone
Note: aObserved interaction.70
N
H3PO4
N
N
N
HN
CN
Figure  2  Ruxolitinib-phosphate,  a  chemical  structure  of  orally  available  Janus   
kinase 1 and 2 inhibitor.
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stromal cells, probably owing to paracrine activity of the 
mesenchymal stromal cells.65 Several point mutations 
identified on a Ba/F3 cell line expressing JAK2V617F may be 
a cause of resistance to ruxolitinib in experimental in vitro 
systems.66
Evidence from preclinical studies in mouse models 
confirmed JAK1 and JAK2 as targets for MF therapy. 
Balb/c mice injected with Ba/F3-EpoR-JAK2V617F cells had 
significant reductions in spleen size, tumor burden, and cir-
culating cytokines when treated with ruxolitinib, compared 
with vehicle treatment.30 In the ruxolitinib-treated mice, the 
histomorphology of affected organs was normalized, and 
anemia and lymphopenia were not detected. More than 90% 
of ruxolitinib-treated mice survived, while by the 22nd day of 
treatment, more than 90% of vehicle-treated mice died.
Pharmacokinetics and metabolism
The pharmacokinetics and metabolism of ruxolitinib were 
established in early studies in healthy volunteers who 
received single doses of 25 mg67 or single or multiple ascend-
ing doses of 5 mg to as much as 200 mg.68 After a single 
oral dose, .95% of the drug is absorbed, and .97% of the 
absorbed drug becomes bound to plasma proteins. Plasma 
concentrations peak 1–3 hours after administration, with 
monophasic or biphasic decline. The terminal half-life is 
2–3 hours. Administration of doses of up to 200 mg demon-
strated dose-proportional exposure.
Ruxolitinib is metabolized predominantly in the liver, 
as a substrate of cytochrome P450 3A4 (CYP3A4), and 
its metabolites are mainly excreted in urine.67,68 There is 
no evidence of accumulation of either ruxolitinib or its 
  metabolites.67 Factors that may influence the pharmacokinetics 
of ruxolitinib have been evaluated. A high-fat meal reduced 
the maximum plasma concentration by 24%, but had no 
substantial influence on bioavailability.68 Because of the 
routes by which ruxolitinib is metabolized and excreted, 
exposure may be increased in patients with impaired 
renal or hepatic function.69,70 When coadministered with 
rifampin (a CYP3A4 inducer), or erythromycin (a moderate 
CYP3A4 inhibitor), no changes in ruxolitinib pharmacokinetics 
were observed in healthy subjects.71 However, in healthy 
subjects who received ruxolitinib concomitantly with 
ketoconazole (a strong CYP3A4 inhibitor), the area under 
the curve increased by 91% and the half-life increased from 
3.7 to 6.0 hours. There is a possibility of similar effects 
when ruxolitinib is coadministered with drugs that are strong 
inhibitors of CYP3A4 (Table 1).72,73
Safety across clinical trials
In healthy volunteers and in patients with MF, myelo-
suppression, and in particular thrombocytopenia, was 
the dose-limiting toxicity of ruxolitinib. The maximum 
tolerated dose was established as 25 mg twice daily (bid) 
and 100 mg once daily (qd).68,74 One healthy volunteer 
receiving a ruxolitinib dose of 50 mg/bid developed high-
grade neutropenia and   recovered 12 days after ruxolitinib 
discontinuation.68 In phase I/II and III clinical trials in 
patients with MF, the most   common hematologic adverse 
effects were   thrombocytopenia and anemia (Table 2).74–78 
  Myelosuppression was dose-  dependent and was not a 
frequent reason for withdrawal.74–76 Dose-dependent 
myelosuppression was not observed in a study of healthy 
volunteers.68 In the blinded, placebo-controlled phase III 
trial, the most frequent nonhematologic adverse events 
reported more commonly for ruxolitinib treatment than for 
placebo were ecchymosis, dizziness, and fatigue (mostly 
grade 1 or 2). Given the mechanism of action of ruxolitinib 
(JAK1/JAK2 inhibition), immunosuppression may be a pos-
sible adverse event; however, this was not observed to an 
appreciable extent in the clinical trials so far.
In a phase I/II clinical trial, investigators described 
clinical symptoms and signs suggesting development of 
systemic inflammatory response syndrome in two patients 
(1.3%) following sudden cessation of ruxolitinib.74 A similar 
reaction was not described among patients in two phase III 
clinical trials.75–77 Nevertheless, recently published phase I/II 
data from one center78,79 describe similar effects of abrupt 
cessation in four patients, and 2 weeks after cessation a 
Table 2 Observed incidence of thrombocytopenia and anemia in clinical trials of ruxolitinib
Treatment group Phase I/II trial73 Phase III COMFORT-I trial75,76 Phase III COMFORT-II trial74
Ruxolitinib Ruxolitinib Placebo Ruxolitinib Best available therapy
nn 82a 155 154 146 73
Thrombocytopenia grade 3 or 4b 3%–29% 12.9% 1.3% 8.3% 7.2%
Anemia grade 3 or 4b 8%–27% 45.2% 19.2% 42.4% 31.4%
Notes: aIncludes only patients on 15 mg/bid and 25 mg/bid regimens; bAccording to Common Terminology Criteria for Adverse Events, version 3.0.
Abbreviation: COMFORT, Controlled Myelofibrosis Study with Oral Janus kinase 1 and 2 Inhibitor Treatment.
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fifth patient developed a syndrome similar to disseminated 
intravascular coagulation with sequential severe polyarticular 
arthritis. Cytokine-rebound phenomena were suggested 
as mechanisms leading to “ruxolitinib discontinuation 
syndrome.” Apart from this one-center experience, such 
events have not been observed by other investigators in any 
other study (∼170 clinical centers). However, to avoid any 
possibility of such complications, it is advisable to taper the 
dose when discontinuing ruxolitinib.78,79
Efficacy in the phase I/II clinical  
trial of ruxolitinib in MF
A phase I/II clinical trial74 of open-label ruxolitinib in MF 
(INCB018424-251; ClinicalTrials.gov, NCT00509899) was 
conducted at two United States centers: the MD Anderson 
Cancer Center in Houston, Texas and the Mayo Clinic 
in Rochester, Minnesota. In all, 153 patients (PMF 53%, 
post-PV MF 32%, and post-ET MF 15%) were enrolled, with 
a median age of 65 years (range, 40–84 years). On the Lille 
scoring system,80 65% of patients were at high risk, 28% at 
intermediate-2 risk, 7% at undetermined risk, and 82% were 
JAK2V617F-positive. In phase I of the study, a maximum toler-
ated dose and dose-limiting toxicity were identified.
In phase II, several dosing regimens, all below the 
maximum tolerated dose, were investigated. Among them, 
15 mg/bid and 25 mg/bid regimens were identified as the 
most appropriate for optimal efficacy and minimal adverse 
effects. In 52% and 49% of the patients on these regimens 
(15 mg/bid and 25 mg/bid, respectively), ruxolitinib reduced 
palpable splenomegaly by $50% from baseline (the study’s 
predefined measure of clinical improvement) after three 
cycles of treatment (one cycle = 4 weeks of daily ruxolitinib). 
Among patients exhibiting this response, the response was 
maintained after 12 months of treatment in 73% of those on 
15 mg/bid and 78% of those on 25 mg/bid. The 15 mg/bid 
regimen was associated with a lower incidence of grade 
3 or 4 thrombocytopenia. In a subset of 24 patients in the 
15 mg/bid group, change in spleen volume was evaluated 
by magnetic resonance imaging (MRI); the median reduc-
tion after six cycles of treatment was 33%, corresponding 
to a median 52% reduction in palpable spleen length. In the 
same MRI substudy, hepatomegaly decreased by 14% in six 
patients with hepatomegaly at baseline.
Patients also demonstrated improvement in other mea-
sures of disease burden. On a 6-minute walk test,81 as per-
formed in 27 patients after 1, 3, and 6 months of treatment, 
median distances walked were 34, 57, and 71 m, respectively. 
Moreover, after a year of treatment, patients on 15 mg/bid and 
25 mg/bid regimens gained weight: a median 9.4 and 7.1 kg, 
respectively. Ruxolitinib recipients with a body mass index in 
the lowest quartile at baseline had the most prominent weight 
gain. In general, improvements in performance status were 
maintained with therapy.
Ruxolitinib treatment also led to decreases in peripheral 
blood cell counts, including CD34-positive cells. In addi-
tion, peripheral blood cytokine levels (of interleukin-1 and 
tumor necrosis factor-alfa) decreased in association with 
improvement of symptoms, while plasma levels of leptin and 
erythropoietin increased. Thirty-four patients were   available 
for evaluation of JAK2V617F allele burden reduction; the mean 
maximal suppression was modest (13% from baseline). 
However, a dose-dependent reduction of constitutively 
phosphorylated STAT3 and STAT5 was observed.
Recently, the two centers participating in this phase 
I/II clinical trial have published separate reports78,82,83 of 
their long-term experience in the treatment of patients with 
MF. For 51 ruxolitinib-treated patients enrolled in the trial 
between October 2007 and February 2009 inclusive, the 
Mayo Clinic in Rochester reported a high discontinuation 
rate: 51%, 72%, and 89% at 1, 2, and 3 years, respectively.78 
As of October 2011, 18 patients (35%) had died and five 
patients (10%) had developed transformation to leukemia. 
Survival rate showed no significant difference between 
the ruxolitinib recipients and a cohort of 410 recipients 
of standard PMF treatment at their center during the past 
decade (P = 0.43).
In contrast, the MD Anderson Cancer Center reported 
that of 107 patients enrolled in the phase I/II trial, 58 (54%) 
were still receiving ruxolitinib at a median of 32 months.82 
As of December 2011, 33 patients (31%) had died, 19 of 
them off-study and none for therapy-related reasons, and 
nine patients (8%) had developed transformation to 
  leukemia, four of them off-study. By log-rank analysis, 
the survival of patients receiving ruxolitinib was signifi-
cantly longer than in a historical cohort of 310 patients 
treated with standard or investigational therapy who would 
have met the phase I/II trial enrollment criteria (hazard 
ratio = 0.61, 95% CI: 0.41–0.89; P = 0.02).83 Survival of 
high-risk ruxolitinib recipients (of whom 21 of 63, or 33%, 
died) was also significantly longer (P = 0.006) than that of 
high-risk patients from the control group (of whom 112 of 
165, or 68%, died). Patients continue to be followed. The 
outcome differences between the cohorts at the two centers 
are possibly related to the inferior efficacy of therapy at the 
Mayo Clinic in Rochester due to lower dosage and shorter 
duration (higher discontinuation rate) of therapy.83
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Phase III clinical trials  
of ruxolitinib in MF
Two phase III clinical trials, the Controlled Myelofibrosis 
Study with Oral JAK1/JAK2 Inhibitor Treatment I and II 
(COMFORT-I76,77 AND COMFORT-II;75 ClinicalTrials.gov, 
NCT00952289 and NCT00934544, respectively), have been 
conducted and are still ongoing.
COMFORT-I is a double-blind, placebo-controlled study 
that enrolled 309 adults with MF in the United States, Canada, 
and Australia. Patients were randomized (1:1) to receive 
ruxolitinib or placebo. Based on baseline peripheral blood 
platelet count (Plt), the ruxolitinib was initiated at 15 mg/bid 
(Plt = 100–200 × 109/L) or 20 mg/bid (Plt . 200 × 109/L). 
Dose adjustment was allowed in accordance with efficacy 
and safety observations during the study, as defined by the 
protocol. At week 24, 41.9% and 0.7% of patients receiving 
ruxolitinib and placebo, respectively, achieved a spleen vol-
ume reduction $ 35% from baseline (the primary endpoint), 
as evaluated by MRI or computed tomography.76,77 Changes 
in symptoms were measured by the modified Myelofibrosis 
Symptom Assessment Form v2.0 Total Symptom Score 
(TSS).84 In the ruxolitinib and placebo arms, respectively, 
45.9% and 5.3% (P , 0.0001) of patients had at least a 
50% improvement in TSS; mean TSS improved by 46.1% 
in the ruxolitinib and worsened by 41.8% in the placebo 
group. All individual symptoms assessed in the Myelofi-
brosis Symptom Assessment Form improved in ruxolitinib 
recipients and worsened in placebo recipients.76,77 The same 
trends of improvements in TSS and reductions in spleen 
volume were observed in subgroup analyses based on MF 
type (PMF, post-PV MF, or post-ET MF), IPSS risk group 
(intermediate-2 or high), age (#65 or .65 years), JAK2V617F 
mutation status (presence or absence), baseline palpable 
spleen length (#10 or .10 cm), and baseline hemoglobin 
level ($10 or ,10 g/dL).85
Quality of life (QoL) was measured by European 
Organization for Research and Treatment of Cancer Quality 
of Life Questionnaire (EORTC QLQ-C30).86 Improvements 
in QoL correlated with the alleviation of symptoms.76–87 
Patients with spleen size reductions of at least 10% realized 
meaningful improvements in symptoms and QoL.87,88
At a median follow-up of 52 weeks in the ruxolitinib and 
51 weeks in the placebo arm, there had been 13 and 24 deaths, 
respectively, with a hazard ratio of 0.50 (95% CI: 0.25–0.98; 
P = 0.04), which provided evidence that ruxolitinib may 
prolong the life of patients with advanced MF.85
COMFORT-II is a double-blind phase III study of 
219 patients with MF, conducted in nine European countries. 
Patients were randomized (2:1) to ruxolitinib or best available 
therapy (BAT). The ruxolitinib dose was 15 mg/bid or 20 mg/
bid, based on the same Plt values as in COMFORT-I, and 
was subject to adjustment within the range of 5 mg/bid to 
25 mg/bid. The BAT could be oral, parenteral, or no therapy. 
Spleen volume reductions of $35% (by MRI or computed 
tomography) at weeks 48 and 24 were the primary and key 
secondary endpoints, respectively. The primary endpoint was 
reached by 28.5% of ruxolitinib and 0% of BAT recipients 
(P , 0.0001), and the key secondary endpoint by 31.9% 
and 0% (P , 0.0001).75 Response rates were also higher for 
ruxolitinib than for BAT in subgroups based on JAK2V617F 
mutational status, risk group, MF type, hydroxyurea pretreat-
ment, baseline spleen size or volume, age, and sex.89
Symptoms measured by the EORTC QLQ-C30 showed 
significant improvements in the ruxolitinib group, starting 
at week 8, with continued improvement through week 48 
versus BAT (P , 0.05).90 Similarly, mean subscores in 
the Functional Assessment of Cancer Therapy–Lymphoma 
System (FACT-LymS)91 improved with ruxolitinib treatment. 
No significant difference was found between risk-based 
subgroups of ruxolitinib recipients.
A post-hoc comparison of the COMFORT-I placebo 
and COMFORT-II BAT groups showed no significant 
difference in symptoms and QoL. In the placebo group, 
median spleen volume increased at week 24 by 8.5% 
(range, −46.4% to +48.8%) and in the BAT group by 5.1% 
(range, −33.3% to +29.7%).92
Conclusion
In clinical trials, ruxolitinib alleviated the burdensome 
manifestations of MF, namely splenomegaly and disease 
core symptoms. Patients experienced reductions in spleen 
size, decreases in circulating pro-inflammatory cytokines, 
increases in weight, and substantial improvements in 
symptoms and QoL. Based on the efficacy and tolerabil-
ity reported in clinical trials, ruxolitinib became the first 
drug approved by the US Food and Drug Administration, 
in mid-November 2011, for the treatment of MF, and now 
has an important place among available treatment options. 
The reported data suggests that its effects are independent 
of patient characteristics including age, MF subtype, 
risk group, JAK2V617F mutation status, baseline palpable 
spleen length, and baseline hemoglobin level. Although 
data from the COMFORT-I phase III clinical trial provides 
evidence that ruxolitinib prolongs the life of patients with 
advanced MF, ruxolitinib does not have a curative poten-
tial in the disease. On the other hand, ruxolitinib seems 
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to offer significant and clinically meaningful benefit over 
other treatment modalities currently used when allogeneic 
hematopoietic stem cell transplantation is not an option. 
Also, it may become useful in pretreating patients deemed 
unfit for allogeneic hematopoietic stem cell transplanta-
tion, perhaps aiding them in becoming clinically fit for 
the transplant procedure. However, this would have to be 
proved in clinical trials. Due to potentially serious adverse 
effects, ruxolitinib should be used under close supervision 
of a physician. Follow-up data from the ruxolitinib phase III 
clinical trials, especially concerning long-term effects and 
survival, are needed to draw any stronger conclusions about 
its enduring benefits in MF. The next wave of clinical 
studies will explore the combination strategies in MF, by 
combining ruxolitinib with other active agents in this dis-
ease, eg, lenalidomide, danazol, erythropoietin, interferon, 
and others, with a goal to bring additional benefits to the 
JAK2 inhibitor therapy, like improvement in blood cell 
count and decrease in bone marrow fibrosis.
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